Daily Stock Analysis, AAAP, Advanced Accelerator Applications SA, priceseries

Advanced Accelerator Applications SA. Daily Stock Analysis
Stock Information
Open
35.91
Close
36.14
High
36.23
Low
35.59
Previous Close
35.90
Daily Price Gain
0.24
YTD High
37.60
YTD High Date
Feb 10, 2017
YTD Low
26.60
YTD Low Date
Jan 3, 2017
YTD Price Change
8.98
YTD Gain
33.06%
52 Week High
39.66
52 Week High Date
Mar 18, 2016
52 Week Low
23.50
52 Week Low Date
Dec 22, 2016
52 Week Price Change
4.14
52 Week Gain
12.94%
Company Information
Stock Symbol
AAAP
Exchange
NasdaqGS
Company URL
www.adacap.com
Company Phone
-
CEO
Stefano Buono
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
-
About

Advanced Accelerator Applications SA is a radiopharmaceutical company which develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. It offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. The firm manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded in 2002 by Stefano Buono and is headquartered in Saint Genis Pouilly, France.

Description

Advanced Accelerator Applications SA is a radiopharmaceutical company that develops, produces and sells molecular nuclear medicine (MNM), diagnostic and therapeutic products. The Company's lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). The Company has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The Company's commercial products include Gluscan /Gluscan 500/Barnascan, IASOflu, IASOdopa, IASOcholine, MIBITEC/Adamibi and Leukokit. Lutathera is a solution of a Lu-177-labeled analogue of somatostatin, a hormone that acts as a regulator of the endocrine system. Somakit is the Company's companion PET diagnostic product candidate for Lutathera. Annexin V-128 is a SPECT diagnostic candidate for the assessment of apoptotic and necrotic processes.